# Albiglutide

Canonical source: https://retacompare.com/encyclopedia/albiglutide

Albumin-fused GLP-1 receptor agonist for once-weekly dosing.

Reference facts

Also known asTanzeum, EperzanCategoryGLP-1 & MetabolicMechanism of actionAlbumin-fused GLP-1 receptor agonist for once-weekly dosing.TargetsGLP-1RIndications under research or approvedType 2 Diabetes (discontinued)Regulatory status (reference entry)Withdrawn 2018 (commercial reasons)Half-life~5 daysSequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRGSequence notesTwo GLP-1(7-36) tandem peptides with Gly8 substitution genetically fused to recombinant human albumin (~73 kDa).Molecular weight (Da)73000Originator / sponsorGlaxoSmithKlineFirst reported2009
    Primary References

HARMONY 8 — Albiglutide vs Sitagliptin, Lancet D&E 2014


    Explore research articles about Albiglutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- HARMONY 8 — Albiglutide vs Sitagliptin, Lancet D&E 2014: https://pubmed.ncbi.nlm.nih.gov/24622752/